About Us

Home  >  About Us  >  Company Overview

Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a clinical program aimed at bringing novel drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries that are engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

Why Invest

  • Tetra is the only company in North America that is working with prescription drug regulators (i.e., Health Canada and FDA) to conduct rigorous clinical trials by bringing pharmaceutical science to the world of medicinal cannabis.
  • As cannabis is a known entity for treating chronic pain, Tetra is able to bypass the long and extensive Phase II clinical trials with Health Canada and have expediency with the FDA.
  • One of the emerging trends in the opioid market is smokable medical marijuana which Tetra plans to bring to market with its lead product PPP001 – a smokable, natural medical cannabis to market for the treatment of chronic pain in cancer patients.
  • While other global pharmaceutical companies have secured approval for cannabis derivatives, nobody has proven to regulators that smokable cannabis has any medical benefits.
  • As the opioid epidemic affects millions in North America and continues to grow, there is an increasing demand for an alternative to opioids such as cannabis-based drugs that will replace the toxic side effect profile of opioids.
  • Tetra plans to develop a superior quality cannabinoid drug product through a scientific process which will thereby create intellectual property (IP) that can be protected via patents.
  • In addition, Tetra also plans on filing the IP for a device with a built-in mechanism for reducing drug abuse.